NCT06378047

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

A Phase 1 Study of Irreversible Electroporation and Pembrolizumab Immunotherapy in Locally Advanced Pancreatic Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to determine the safety and tolerability of combining sequential therapy of Irreversible Electroporation (IRE) and Immunotherapy (IO) for patients with locally advanced unresectable pancreas cancer following first-line treatment with chemotherapy and ablative stereotactic magnetic resonance image-guided adaptive radiation therapy (A-SMART).

Conditions

• Pancreatic Cancer
• Locally Advanced Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	Pembrolizumab	Pembrolizumab is an immunotherapy that will be administered via IV infusion.
DEVICE	Irreversible Electroporation	Participants will undergo IRE as standard of care treatment.

Timeline

• Start date: 2024-04-10
• Primary completion: 2025-09-15
• Completion: 2025-09-15
• First posted: 2024-04-22
• Last updated: 2026-02-09

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study